Thermo Fisher Scientific Expands Offering for Clinical Applications at AACC 2016
August 01 2016 - 08:00AM
Business Wire
New products and applications designed to
accelerate innovation and increase productivity in research and
clinical settings
AACC 2016 – Thermo Fisher Scientific Inc.
(NYSE:TMO), the world leader in serving science, will exhibit its
expanded offering of new assays, instruments and software at the
2016 American Association of Clinical Chemistry (AACC) Annual
Meeting and Clinical Lab Expo being held July 31 - August 4 at the
Pennsylvania Convention Center. Designed specifically for customers
working in research and clinical settings, these innovative new
products will be on display in booths #2334 and
#2145.
“Today’s healthcare and clinical service providers are on the
front line of a rapidly changing diagnostic landscape,” said Marc.
N Casper, president and chief executive officer of Thermo Fisher
Scientific. “Our commitment to innovation in specialty diagnostics
enables these customers to meet the growing demand for more rapid,
sensitive and cost-effective tests that lead to better outcomes for
patients.”
The impact of opioid abuse on communities places an increasing
burden on the healthcare system as well as the law enforcement
community. The new Thermo Scientific DRI Hydrocodone assay
offers greater sensitivity to help clinicians obtain faster, more
accurate test results. This 510(k)-cleared assay detects
hydrocodone in specimen samples. With an increased level of
sensitivity, the DRI Hydrocodone assay meets the recently proposed
Substance Abuse and Mental Health Administration (SAMHSA) testing
guidelines for drugs of abuse.
To help prevent sepsis in hospital patients, a growing concern
for clinicians, the company announced that its Thermo Scientific
B·R·A·H·M·S Procalcitonin (PCT) assay can now be used in the
emergency room or hospital ward to aid in risk assessment for
patients prior to their admission to the intensive care unit.
Through a novel clinical study, the U.S. Food and Drug
Administration (FDA) has expanded Thermo Fisher’s clearance for the
use of the PCT assay to support mortality risk assessment over
multiple days. The B·R·A·H·M·S PCT test takes just 20 minutes,
allowing results to be rapidly available to determine the risk of
progression in septic patients and support appropriate clinical
decision-making.
For in vitro diagnostics, the company is highlighting its new
Thermo Scientific Prelude LX-4 MD HPLC (high performance liquid
chromatography) multi-channel instrument, which is listed with
the FDA as a class I medical device for general clinical use.
Designed to increase productivity and efficiency of clinical sample
separations, the Prelude LX-4 MD can run mass spectrometry assays
simultaneously for fast, accurate in vitro diagnostic tests.
Thermo Fisher has also received 510(k) clearance from the FDA
for two new EliA IgG tests for detecting anti-Thyroglobulin
(anti-TG) and anti-Thyroid Peroxidase (anti-TPO) autoantibodies in
serum or plasma. Thyroid autoimmunity includes a number of distinct
but related autoimmune disorders of the thyroid gland, such as
Graves’ disease or Hashimoto’s thyroiditis. Both tests will be
featured in the Thermo Fisher booth.
Finally, the new Thermo Scientific LabLink xL 2.0 quality
assurance software, in conjunction with Thermo Scientific MAS
quality controls, is designed to ensure more accurate results in
clinical chemistry methods. This Cloud-based resource allows
clinicians to compare and validate control results from labs around
the world in real time.
More information on Thermo Fisher Scientific products and events
at AACC 2016 can be found at news.thermofisher.com.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving
science, with revenues of $17 billion and more than 50,000
employees in 50 countries. Our mission is to enable our customers
to make the world healthier, cleaner and safer. We help our
customers accelerate life sciences research, solve complex
analytical challenges, improve patient diagnostics and increase
laboratory productivity. Through our premier brands – Thermo
Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and
Unity Lab Services – we offer an unmatched combination of
innovative technologies, purchasing convenience and comprehensive
support. For more information, please visit
www.thermofisher.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160801005374/en/
Thermo Fisher ScientificRon O’Brien,
781-622-1242ron.obrien@thermofisher.comorThermo Fisher
ScientificKen Apicerno,
781-622-1294ken.apicerno@thermofisher.com
Thermo Fisher Scientific (NYSE:TMO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Thermo Fisher Scientific (NYSE:TMO)
Historical Stock Chart
From Mar 2023 to Mar 2024